Policy & access
Current UK medical cannabis policy and access campaigns
Campaign proposals can explain pressure for change, but they are not current law. This page separates the present specialist-prescriber framework from reforms being requested by sector organisations.
The current official review.
The Home Office’s ACMD work programme includes a review of CBPM legislation and whether the November 2018 changes had the intended impact. The review can produce advice and recommendations; it does not itself amend the law.
Campaign: broaden who can initiate prescribing.
The Cannabis Industry Council’s “Protect our Patients” campaign calls for GPs to have the same CBPM prescribing rights as specialist medical practitioners. The CIC has also advocated electronic prescribing and routes connecting NHS consultations with private prescriptions.
The current framework still requires an unlicensed CBPM prescription or direction from a doctor on the GMC Specialist Register. GreenGuruAI links the campaign so readers can understand the proposal, not to endorse it.
How to assess an access campaign.
- Who published it, funds it and benefits from the requested change?
- Is it asking for legislation, regulator guidance, NHS commissioning or professional-practice change?
- What evidence and counterarguments does it cite?
- Has government accepted, rejected or not yet responded?
- Does the proposal preserve product quality, prescribing accountability and continuity?
What patients can rely on today.
Use current government, regulator and professional guidance for access decisions. Treat campaign pages as dated evidence of advocacy. GreenGuruAI will update this page when an official review, consultation response or legislative change alters the position.
Primary sources
Independent review
Qualified reviewer?
GreenGuruAI welcomes source-specific corrections and independent review from UK clinicians, pharmacists and solicitors with relevant expertise. Review being invited does not mean review is complete or imminent.
Contact GreenGuruAI →